GO2 for Lung Cancer

🌟 After being diagnosed with early-stage #LungCancer nearly 20 years ago, Dusty underwent a #lobectomy and #chemotherapy. Thankfully, she has had no evidence of disease (NED) ever since. Her “boring” story inspired her to become an advocate. Her goal? That everyone diagnosed with lung cancer has the same outcome. Today, Dusty is a passionate voice for increased federal research funding, joining GO2’s Voices Summit in Washington, D.C. every year to make a difference. Your voice matters, too. Learn more about Dusty’s story and how you can join her this March at the Voices Summit. 👉🏻 https://lnkd.in/eaEHDvy5

🌟 Diagnosed with stage 3 (III) EGFR lung cancer at just 28, Aurora’s journey highlights the barriers young people often face when seeking a #diagnosis. From insurance delays to stigma around #LungCancer, her resilience and determination are remarkable. Aurora’s experience inspired her to become an advocate, and attending the 2024 Voices Summit strengthened her commitment to raising awareness and fighting for equity in care. Read Aurora’s inspiring story: https://lnkd.in/e9WJa5F7

Are you or a loved one affected by lung cancer? You’re not alone. Join our Gathering HOPE virtual group to connect with others, share stories of encouragement, and build meaningful friendships. 📆 When? 2nd Tuesday of each month at 5 p.m. PT/8 p.m. ET 📍 Where? On Zoom – from the comfort of your home! 🔗 Register now: https://lnkd.in/enQj7pJt We can’t wait to see you there! ✨

It is with profound sadness that we honor the life and legacy of Diane Daniels Legg, a trailblazer in the fight against lung cancer. Diane passed away in late December after surviving lung cancer for over two decades. Diagnosed purely by chance in 2004 with stage 1 non-small cell lung cancer, Diane transformed her diagnosis into a mission to change the realities surrounding the disease: the stigma, lack of research funding, limited screening, and insufficient awareness. She became a tireless advocate, educator, and supporter for others affected by lung cancer. Diane’s efforts were instrumental in shaping our organization’s early advocacy work. As a key leader with the Lung Cancer Alliance (now GO2 for Lung Cancer), she championed policies that have led to over $220 million in dedicated federal funding for lung cancer research and screening. She also helped establish programs to support patients, raise awareness, and fund vital research, including the first Shine a Light on Lung Cancer® event in Boston. This initiative has grown into the largest global awareness campaign taking place each year during Lung Cancer Awareness Month, with 255 events across 50 states and multiple countries. Diane’s vision, courage, and determination have left a lasting impact on the lung cancer community and beyond. We extend our deepest sympathies to the Legg and Daniels families and her countless friends and supporters. Diane’s legacy continues to inspire us as we strive toward her ultimate vision: a world without lung cancer.

On December 27, 2024, the FDA approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous injection. This new administration method allows for a faster treatment experience, just 5 minutes versus the standard 30-minute IV infusion, and has shown a slightly improved response rate with no difference in safety. This advancement could have a meaningful impact on patients with non-small cell lung cancer (NSCLC). Explore the details of this milestone in treatment options by reading our latest blog: https://lnkd.in/eZVifp8Q

Thank you for confronting lung cancer with us at a time when profound lifesaving change is not only possible but achievable. As we step into 2025, we remain committed to advancing research, supporting our community of people living with and at risk for #LungCancer and their loved ones, and advocating for increased research funding. We are more optimistic than ever about transforming lung cancer survival. 🩵

Have you set your 2️⃣0️⃣2️⃣5️⃣ goals? One of ours is clear: increasing federal funding for lung cancer research—and we need your help to make it happen! GO2's Voices Summit is back this March, in Washington, D.C.! This is your chance to connect with others impacted by lung cancer, get training, and advocate directly with policymakers. Together, we can make a difference by increasing funding for life-saving research and improving access to affordable care. 📅 Date: March 9-11 📍 Location: Washington, D.C. 💻 Register now: go2.org/voicessummit Let’s move the needle on lung cancer research and legislation this year. Your voice matters—join us!

While the genetic risk for cancers such as breast, ovarian, colon, and prostate cancers has been studied extensively, relatively little is known about any genetic risk for developing lung cancer. This is true for cases related to tobacco exposure, and especially for those that are not. In the INHERIT Study, we will study patients and families with either known germline mutations or elevated rates of lung cancer and try to understand the basis for any inherited or genetic risk. Our goals are to learn more about the genetic risk for lung cancer, how to better predict lung cancer risk in the context of family history or certain germline mutations, and ways to employ potential lung cancer screening in these populations. To join our research study or to see how you can collaborate with our study team for this important research, please visit the study website at inheritstudy.org.

This season, we’re sending warm wishes to you and your loved ones. We hope your holidays are filled with joy, peace, and hope. 🩵✨

Making informed decisions about your lung cancer care starts with knowledge and partnership. 🩺💡 In our latest Lung Cancer Living Room®, David Gandara, MD, of UC Davis Comprehensive Cancer Center discusses the importance of shared decision-making and seeking a second opinion. Key highlights include: 🔹 The value of biomarker testing in guiding personalized treatment options. 🔹 How tumor boards collaborate to offer expert recommendations. 🔹 Exploring newer treatment options, including targeted therapies and immunotherapies. 👀 Don’t miss this engaging conversation with Dr. Gandara and GO2’s Chief Patient Officer, Danielle Hicks, designed to empower you in your care journey. Read the blog and watch the full discussion here: https://lnkd.in/eGQ8usbd